Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1501473rdf:typepubmed:Citationlld:pubmed
pubmed-article:1501473lifeskim:mentionsumls-concept:C0042037lld:lifeskim
pubmed-article:1501473lifeskim:mentionsumls-concept:C0025611lld:lifeskim
pubmed-article:1501473lifeskim:mentionsumls-concept:C0002658lld:lifeskim
pubmed-article:1501473lifeskim:mentionsumls-concept:C0014479lld:lifeskim
pubmed-article:1501473lifeskim:mentionsumls-concept:C0031495lld:lifeskim
pubmed-article:1501473lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:1501473lifeskim:mentionsumls-concept:C0020980lld:lifeskim
pubmed-article:1501473lifeskim:mentionsumls-concept:C0680536lld:lifeskim
pubmed-article:1501473pubmed:issue4lld:pubmed
pubmed-article:1501473pubmed:dateCreated1992-9-17lld:pubmed
pubmed-article:1501473pubmed:abstractTextWe evaluated six commercially available amphetamine (A) and methamphetamine (MA) immunoassays for their relative cross-reactivities to isomers of phenylpropanolamine (PPA) and ephedrine (E) in urine: Syva EMIT, Abbott fluorescence polarization (FPIA), Roche, and Diagnostic Products Corporation (DPC) radioimmunoassays for A and MA. Two stereoisomers of PPA and four stereoisomers of E were tested using (1) drug-free urine spiked at 1,000 mg/L or 100 mg/L of each compound and (2) 60 clinical urine specimens not containing A or MA but having varying amounts of PPA and/or E. Specimens responding greater than the 1-mg/L A or MA cutoff were defined as positive. All specimens spiked at 100 mg/L were negative by all immunoassays. All specimens spiked at 1,000 mg/L were positive by EMIT and negative by FPIA, Roche A, and DPC A; 1,000 mg/L/-E and d-pseudoephedrine were also positive by Roche MA and DPC MA. Three of the 60 clinical specimens tested positive by EMIT and one specimen tested positive by DPC A and DPC MA.lld:pubmed
pubmed-article:1501473pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1501473pubmed:languageenglld:pubmed
pubmed-article:1501473pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1501473pubmed:citationSubsetIMlld:pubmed
pubmed-article:1501473pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1501473pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1501473pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1501473pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1501473pubmed:statusMEDLINElld:pubmed
pubmed-article:1501473pubmed:issn0146-4760lld:pubmed
pubmed-article:1501473pubmed:authorpubmed-author:LevineBBlld:pubmed
pubmed-article:1501473pubmed:authorpubmed-author:JonesRRlld:pubmed
pubmed-article:1501473pubmed:authorpubmed-author:SmithM LMLlld:pubmed
pubmed-article:1501473pubmed:authorpubmed-author:D'NicuolaJJlld:pubmed
pubmed-article:1501473pubmed:issnTypePrintlld:pubmed
pubmed-article:1501473pubmed:volume16lld:pubmed
pubmed-article:1501473pubmed:ownerNLMlld:pubmed
pubmed-article:1501473pubmed:authorsCompleteYlld:pubmed
pubmed-article:1501473pubmed:pagination211-3lld:pubmed
pubmed-article:1501473pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:1501473pubmed:meshHeadingpubmed-meshheading:1501473-...lld:pubmed
pubmed-article:1501473pubmed:meshHeadingpubmed-meshheading:1501473-...lld:pubmed
pubmed-article:1501473pubmed:meshHeadingpubmed-meshheading:1501473-...lld:pubmed
pubmed-article:1501473pubmed:meshHeadingpubmed-meshheading:1501473-...lld:pubmed
pubmed-article:1501473pubmed:meshHeadingpubmed-meshheading:1501473-...lld:pubmed
pubmed-article:1501473pubmed:meshHeadingpubmed-meshheading:1501473-...lld:pubmed
pubmed-article:1501473pubmed:meshHeadingpubmed-meshheading:1501473-...lld:pubmed
pubmed-article:1501473pubmed:meshHeadingpubmed-meshheading:1501473-...lld:pubmed
pubmed-article:1501473pubmed:meshHeadingpubmed-meshheading:1501473-...lld:pubmed
pubmed-article:1501473pubmed:meshHeadingpubmed-meshheading:1501473-...lld:pubmed
pubmed-article:1501473pubmed:meshHeadingpubmed-meshheading:1501473-...lld:pubmed
pubmed-article:1501473pubmed:meshHeadingpubmed-meshheading:1501473-...lld:pubmed
pubmed-article:1501473pubmed:meshHeadingpubmed-meshheading:1501473-...lld:pubmed
pubmed-article:1501473pubmed:meshHeadingpubmed-meshheading:1501473-...lld:pubmed
pubmed-article:1501473pubmed:meshHeadingpubmed-meshheading:1501473-...lld:pubmed
pubmed-article:1501473pubmed:articleTitleEvaluation of six commercial amphetamine and methamphetamine immunoassays for cross-reactivity to phenylpropanolamine and ephedrine in urine.lld:pubmed
pubmed-article:1501473pubmed:affiliationDivision of Forensic Toxicology, Armed Forces Institute of Pathology, Washington, DC 20306-6000.lld:pubmed
pubmed-article:1501473pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1501473pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:1501473pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1501473lld:pubmed